Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas

Ferraris, AM; Giuntini, P; Gaetani, Gian Franco

doi:10.1182/blood.v54.4.928.928

Cited by 104 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the current study, the LDH values at presentation had a predictive value for attainment of CR status, although this trend was not significant. The relationship between LDH values and survival has previously been reported by Magrath et al (1980) andby Ferrais et al (1979).…”

Section: Discussionmentioning

confidence: 96%

Heterogeneity of response and survival in diffuse histiocytic lymphoma after bacop therapy (bleomycin, doxorubicin, cyclophosphamide, vincristine, prednisone)

Levine

Goldstein

Meyer

et al. 1985

Hematological Oncology

View full text Add to dashboard Cite

Diffuse 'histiocytic' lymphoma (DHL) is heterogeneous pathologically, consisting of four subtypes within Lukes-Collins; large-cleaved (LC), large non-cleaved (LNC), immunoblastic sarcoma of B cells (B-IBS), and immunoblastic sarcoma of T-cells (T-IBS). This heterogeneity is also recognized in the Cooperative Working Formulation on non-Hodgkin's lymphoma. Prior studies have suggested clinical heterogeneity of DHL as well, although conclusions were hampered by small numbers, and lack of therapeutic uniformity. We treated 57 patients with advanced DHL, using BACOP: 22 LNC, 16 T-IBS, 13 B-IBS, six LC. Complete remission rate for LNC was 64 per cent (14/22); B-IBS was 54 per cent (7/13); LC was 33 per cent (2/6); T-IBS was 25 per cent (4/16). (p = 0.10). Median survival for LNC was 27.8 months, B-IBS was 25.9, LC was 14, T-IBS was 12.0. The survival was significantly shorter for T-IBS patients when compared to the others (p = 0.01). By multi-variate analysis, histologic subtype (p = 0.02), age (p = 0.03), and stage (p = 0.06) were significant and independent prognostic variables in predicting survival. We conclude that LNC may respond the most favourably to BACOP, whereas alternative regimens appear necessary for patients with T-IBS.

show abstract

Section: Discussionmentioning

confidence: 96%

Heterogeneity of response and survival in diffuse histiocytic lymphoma after bacop therapy (bleomycin, doxorubicin, cyclophosphamide, vincristine, prednisone)

Levine

Goldstein

Meyer

et al. 1985

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…3). Serum LDH level may be associated with tumor microenvironment including various immune cells as well as tumor burden and aggressiveness in lymphoid malignancy 32 , and its negative prognostic value is well-documented in patients with Hodgkin or non-Hodgkin lymphoma [32][33][34] .…”

Section: Discussionmentioning

confidence: 99%

Reappraisal of the prognostic value of Epstein-Barr virus status in monomorphic post-transplantation lymphoproliferative disorders–diffuse large B-cell lymphoma

Kim

Cho

Sung

et al. 2021

Sci Rep

View full text Add to dashboard Cite

The role of the Epstein-Barr virus (EBV) status in the blood for predicting survival in post-transplantation lymphoproliferative disorders–diffuse large B-cell lymphoma (PTLD–DLBCL) is unknown. We evaluated the prognostic values of pre-treatment EBV-encoded small RNA (EBER) detected with in situ hybridization in tissues and EBV DNA in the whole blood (WB) and plasma in 58 patients with monomorphic PTLD–DLBCL after solid organ transplantation. There were no significant differences in the rates of overall response, complete response, and survival according to EBER EBV and WB EBV status. In contrast, patients with positive plasma EBV DNA had significantly lower rates of overall response (60.0% vs. 94.4%, P = 0.043) and complete response (40.0% vs. 88.9%, P = 0.019) as well as worse progression-free survival (PFS) (P = 0.035) and overall survival (OS) (P = 0.039) compared with patients with negative plasma EBV DNA. In multivariate analysis, plasma EBV DNA positivity was a significantly unfavorable prognostic factor for PFS [hazard ratio (HR) 4.92, 95% confidence interval (CI) 1.22–19.86, P = 0.025] and OS (HR 4.48, 95% CI 1.14–17.63, P = 0.032). Despite small number of 6 patients with plasma EBV positivity, plasma EBV DNA positivity might be more prognostic for survival than EBER or WB EBV DNA positivity in patients with monomorphic PTLD–DLBCL.

show abstract

“…LDH is also a well-known biomarker. The level of LDH was found to be elevated related to a wide spectrum of disease and was reported to be 100-240 mU in normal serum [31]. L-lactate dehydrogenase B as one subunit of LDH was also reported to be elevated under some diseases conditions [32,33].…”

Section: Detection Of Low-abundance Proteinsmentioning

confidence: 99%

Developing a strong anion exchange/RP (SAX/RP) 2D LC system for high-abundance proteins depletion in human plasma

et al. 2012

View full text Add to dashboard Cite

Human plasma is dominated by high-abundance proteins which severely impede the detection of low-abundance proteins. Unfortunately, now there is no efficient method for large-scale depletion of high-abundance proteins in human plasma. In this study, we developed a new strategy, strong anion exchange (SAX)/RP 2D LC system, which has potential for large-scale depletion of high-abundance proteins in human plasma. Separation gradients of the system were optimized to ensure an extensive separation of plasma proteins. Plasma was fractionated into 67 fractions by SAX. All these fractions were subjected a thorough separation by the 2D RPLC and 66 peaks with high UV absorption (>20 mAU) at 215 nm were collected. Proteins in these peaks were identified by LC-MS/MS analysis. Results showed that 83 proteins could be identified in these peaks, 68 among them were reported to be high- or middle-abundance proteins in plasma. All these proteins had definite retention times and were mapped in the 2D SAX-RP system, which resulted in accurate depletion of high-abundance proteins with ease. Our studies provide a convenient and effective method for large-scale depletion of high-abundance proteins and in-depth research in human plasma proteomics.

show abstract

Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas

Cited by 104 publications

References 0 publications

Heterogeneity of response and survival in diffuse histiocytic lymphoma after bacop therapy (bleomycin, doxorubicin, cyclophosphamide, vincristine, prednisone)

Heterogeneity of response and survival in diffuse histiocytic lymphoma after bacop therapy (bleomycin, doxorubicin, cyclophosphamide, vincristine, prednisone)

Reappraisal of the prognostic value of Epstein-Barr virus status in monomorphic post-transplantation lymphoproliferative disorders–diffuse large B-cell lymphoma

Developing a strong anion exchange/RP (SAX/RP) 2D LC system for high-abundance proteins depletion in human plasma

Contact Info

Product

Resources

About